Vaxart VXRT Stock
Vaxart Price Chart
Vaxart VXRT Financial and Trading Overview
| Vaxart stock price | 0.41 USD |
| Previous Close | 0.44 USD |
| Open | 0.45 USD |
| Bid | 0.41 USD x 600000 |
| Ask | 0.42 USD x 250000 |
| Day's Range | 0.41 - 0.45 USD |
| 52 Week Range | 0.31 - 0.84 USD |
| Volume | 180.88K USD |
| Avg. Volume | 276.99K USD |
| Market Cap | 99.92M USD |
| Beta (5Y Monthly) | 1.057 |
| PE Ratio (TTM) | 2.4117646 |
| EPS (TTM) | 0.17 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | November 9, 2012 |
| 1y Target Est | 3.33 USD |
VXRT Valuation Measures
| Enterprise Value | 48.12M USD |
| Trailing P/E | 2.4117646 |
| Forward P/E | -0.39805827 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.41107208 |
| Price/Book (mrq) | 1.2094395 |
| Enterprise Value/Revenue | 0.198 |
| Enterprise Value/EBITDA | 1.055 |
Trading Information
Vaxart Stock Price History
| Beta (5Y Monthly) | 1.057 |
| 52-Week Change | 13.88% |
| S&P500 52-Week Change | 10.88% |
| 52 Week High | 0.84 USD |
| 52 Week Low | 0.31 USD |
| 50-Day Moving Average | 0.48 USD |
| 200-Day Moving Average | 0.59 USD |
VXRT Share Statistics
| Avg. Volume (3 month) | 276.99K USD |
| Avg. Daily Volume (10-Days) | 295.27K USD |
| Shares Outstanding | 243.7M |
| Float | 239.25M |
| Short Ratio | 1.87 |
| % Held by Insiders | 1.45% |
| % Held by Institutions | 0.054% |
| Shares Short | 16.96M |
| Short % of Float | 7.51% |
| Short % of Shares Outstanding | 7.40% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:11 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 15.87% |
| Operating Margin (ttm) | -48.45% |
| Gross Margin | 24.19% |
| EBITDA Margin | 18.76% |
Management Effectiveness
| Return on Assets (ttm) | 15.03% |
| Return on Equity (ttm) | 66.96% |
Income Statement
| Revenue (ttm) | 243.06M USD |
| Revenue Per Share (ttm) | 1.03 USD |
| Quarterly Revenue Growth (yoy) | -31.60% |
| Gross Profit (ttm) | 58.8M USD |
| EBITDA | 45.62M USD |
| Net Income Avi to Common (ttm) | 38.59M USD |
| Diluted EPS (ttm) | 0.17 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 63.98M USD |
| Total Cash Per Share (mrq) | 0.26 USD |
| Total Debt (mrq) | 12.54M USD |
| Total Debt/Equity (mrq) | 15.22 USD |
| Current Ratio (mrq) | 1.596 |
| Book Value Per Share (mrq) | 0.339 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 33.98M USD |
| Levered Free Cash Flow (ttm) | -17148376 USD |
Profile of Vaxart
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 310 Utah Avenue |
| ZIP | 94080 |
| Phone | 650 550 3500 |
| Website | https://vaxart.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 65 |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Q&A For Vaxart Stock
What is a current VXRT stock price?
Vaxart VXRT stock price today per share is 0.41 USD.
How to purchase Vaxart stock?
You can buy VXRT shares on the OTC Markets OTCQX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vaxart?
The stock symbol or ticker of Vaxart is VXRT.
Which industry does the Vaxart company belong to?
The Vaxart industry is Biotechnology.
How many shares does Vaxart have in circulation?
The max supply of Vaxart shares is 243.7M.
What is Vaxart Price to Earnings Ratio (PE Ratio)?
Vaxart PE Ratio is 2.38235280 now.
What was Vaxart earnings per share over the trailing 12 months (TTM)?
Vaxart EPS is 0.17 USD over the trailing 12 months.
Which sector does the Vaxart company belong to?
The Vaxart sector is Healthcare.
Vaxart VXRT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26169.38 USD — |
+0.82
|
6.51B USD — | 25986.56 USD — | 26306.82 USD — | — - | 6.51B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
114.93 USD — |
-0.18
|
— — | 114.49 USD — | 115.91 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1333.33 USD — |
+0.41
|
— — | 1325.41 USD — | 1341.7 USD — | — - | — — |
- {{ link.label }} {{link}}
